To prospectively and directly compare the capability of whole-body diffusion-weighted (DW) imaging, whole-body magnetic resonance (MR) imaging with and that without DW imaging, and integrated fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for M-stage assessment in nonsmall cell lung cancer (NSCLC) patients.
L
ung cancer is the most common cause of cancer-related death among both men and women worldwide (1) . Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancers, and small cell lung cancer accounts for the remainder (2) . The treatment regimen for NSCLC depends on preoperative TNM staging, with curative surgical resection possible for the early stages and chemoradiotherapy, chemotherapy, or best supportive care considered advisable for the later stages, depending on the patient's performance status (3, 4) . Accurate tumor staging is therefore essential for choosing the appropriate treatment strategy, because it provides prognostic information and influences treatment options for patients with NSCLC.
Whole-body positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose (FDG) has rapidly become accepted as the standard noninvasive modality for staging lung cancer in patients. Although PET has been shown to be superior to computed tomography (CT) for the staging of lung cancer, in reality PET and CT are complementary modalities whose combined diagnostic value is superior to that of either study alone (5) . In addition, technologic advances have promoted integrated PET/CT as the new modality in the arsenal of cancer staging. Given the novelty of PET/CT, the number of studies involving the comparison of PET and PET/CT of NSCLC is still limited but is growing. Studies (6) (7) (8) have revealed the superior accuracy attained with integrated PET/CT over that with PET alone for overall staging and diagnosis of NSCLC.
Whole-body magnetic resonance (MR) imaging has been put forward as another whole-body technique for the assessment of distant metastases in patients with lung cancer, as well as those with breast cancer, malignant melanoma, and pediatric and other malignancies (9) (10) (11) (12) (13) (14) . Advantages of wholebody MR imaging include no need for ionizing radiation exposure, information from various sequences without and with administration of contrast media, improved temporal resolution due to a newly developed parallel imaging technique, a moving table scheme and/or multiple body-array coils, and suggested utility of MR imaging in various organs compared with CT and nuclear medicine studies. In addition, some investigators (15) (16) (17) (18) (19) (20) have suggested that the diagnostic capability of MR imaging is equal to or better than that of standard radiologic examinations including contrast material-enhanced CT, bone scintigraphy, and/or FDG PET for the assessment of brain, bone, bone marrow, and adrenal gland metastases in oncology patients. Moreover, it has been suggested that diffusion-weighted (DW) imaging could be useful for the assessment of primary malignancy (21, 22) and lymph node and/or distant metastases (23, 24) , as well as for detection of additional benign and/or malignant tumors (25, 26) , although DW imaging is widely utilized for evaluation of cerebral abnormalities (27) (28) (29) (30) . Diffusion is a physical property that describes the microscopic random movement of molecules in response to thermal energy. Also known as brownian motion, diffusion may be affected by the biophysical properties of tissues, such as cell organization and density, microstructures, and microcirculation. However, to our knowledge, no direct comparison has been made between the
Advances in Knowledge
Ⅲ When compared with integrated fluorine 18 fluorodeoxyglucose (FDG) PET/CT on a per-patient basis, interobserver agreement and mean reading time of wholebody MR imaging with diffusionweighted (DW) imaging were almost the same. Ⅲ A comparison of capability for M-stage assessment with the inclusion of brain metastases showed that diagnostic accuracies of whole-body DW imaging was significantly lower than that of integrated FDG PET/CT. Ⅲ A comparison of capability for M-stage assessment with the exclusion of brain metastases showed that diagnostic accuracy of whole-body DW imaging and whole-body MR imaging without DW imaging were significantly lower than that of integrated FDG PET/CT. Ⅲ If whole-body DW imaging is adopted as an adjunct for wholebody MR examination, the diagnostic capability of whole-body MR imaging for M-stage assessment can be improved, especially when evaluation of brain metastases at whole-body MR imaging is not included.
Implications for Patient Care
Ⅲ Whole-body MR imaging with DW imaging can be used for Mstage assessment of patients with non-small cell lung cancer with accuracy as good as that of integrated PET/CT. Ⅲ When whole-body DW imaging is adopted as an adjunct for wholebody MR examination, the diagnostic capability of whole-body MR imaging for M-stage assessment can be improved, especially when evaluation of brain metastases at whole-body MR imaging is not included. In this study, we attempted to validate the hypothesis that whole-body MR imaging with DW imaging has potential as an alternative technique for the detection of distant metastases in patients with NSCLC with a capability similar to that of integrated FDG PET/CT. However, in oncology patients, utilization of FDG PET or PET/CT has been limited to assessment of brain metastases in routine clinical practice. Therefore, direct comparison of the diagnostic accuracy for M-stage assessment with the inclusion of and with the exclusion of brain metastases is important for the determination of the actual utility of wholebody MR examinations. To this end, we prospectively and directly compared the capability of whole-body MR imaging with and that without DW imaging with that of integrated FDG PET/CT for Mstage assessment with the inclusion of and with the exclusion of brain metastases in patients with NSCLC and determined the utility of whole-body DW imaging as a component of whole-body MR examination for detection of metastases.
Materials and Methods

Protocol, Support, and Funding
This prospective study was approved by the institutional review board of Kobe University Hospital and was partly supported by Eizai (Tokyo, Japan) (Y. Ohno, K.S.), Philips Medical Systems (Best, the Netherlands) (Y. Ohno, K.S.), and the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Subjects
All patients were enrolled after they had been properly informed and had consented to participate in this study. A total of 227 consecutive patients (118 men, 109 women; mean age, 73 years), who were referred to our hospital with a diagnosis of NSCLC at pathologic examination and who were considered candidates for surgical resection, underwent prospective whole-body MR imaging with and that without DW imaging, integrated FDG PET/CT, and conventional radiologic imaging before treatment. All studies were performed in random order within 3 weeks of diagnosis and before treatment. Follow-up examinations were performed for more than 12 months after treatment.
The eventual study group of 203 patients (mean age, 72 years; age range, 47-85 years) comprised 109 men (mean age, 72 years; age range, 47-81 years) and 94 women (mean age, 72 years; age range, 49 -85 years) because 24 patients were excluded due to insufficient or no follow-up examinations after treatment. The final diagnosis of NSCLC was made on the basis of findings from histologic examinations of specimens obtained by using transbronchial or CT-guided biopsy or on the basis of pathologic findings of resected specimens obtained at surgical resection at our hospital. There were 176 patients with adenocarcinomas, 19 with squamous cell carcinomas, and eight with large cell carcinomas. 
Whole-Body MR Imaging
Integrated FDG PET/CT Examination for Initial Staging and Follow-up Examination
All patients fasted for at least 6 hours before intravenous administration of FDG at a rate of 3.3 MBq/kg, and images were obtained from the skull to the midthigh 60 minutes after completion of the injection. All FDG PET/CT examinations were performed with a commercially available PET/CT scanner (Discovery ST; GE Healthcare, Milwaukee, Wis). The axes of the multidetector CT and PET systems were mechanically aligned so that the patient could be moved All integrated PET/CT examinations were performed within 60 minutes. The CT data were resized from a 512 ϫ 512 matrix to a 128 ϫ 128 matrix to match the PET data so that the scans could be fused and CT-based transmission maps could be generated. PET data sets were reconstructed iteratively with an ordered-subsets expectation maximization algorithm and segmented attenuation correction (two iterations, 21 subsets) and with CT data. Coregistered scans were displayed by means of commercially available software (Fusion Viewer; Nihon Medi-Physics, Nishinomiya, Japan).
Conventional Radiologic Examination and Final Diagnosis of M Stage
The conventional radiologic examinations for M-stage assessment performed during the initial and the follow-up examinations included brain MR imaging with administration of contrast medium, contrast-enhanced whole-body CT, and bone scintigraphy.
The final M stage and metastasis of a given site were determined on the basis of the results of conventional radiologic, integrated FDG PET/CT, and wholebody MR examinations and on the basis of pathologic results from endoscopic, CT-guided, or surgical biopsies, as well as on the basis of results of follow-up examinations performed for more than 12 months in every patient. The lesions suspected of being metastases on the basis of initial radiologic examination results were diagnosed as metastases when the tissues were proved to be metastatic at pathologic examination or the lesions became larger during the follow-up periods or decreased in size after treatment. The lesions suspected of being metastases on the basis of initial radiologic examination results and that could not be diagnosed as metastatic sites at pathologic examination were observed for more than 12 months and diagnosed as nonmetastatic sites when no change in size was observed during the follow-up period of more than 12 months or during treatment periods. The final determination of M stage and metastasis of a given site was made by consensus at a conference attended by diagnostic radiologists, radiation oncologists, pathologists, oncologists, and surgeons with more than 11 years of experience (range, 11-28 years).
Image Analysis
All images were interpreted by means of a picture archiving and communication system (ShadeQuest; Yokogawa Electric, Tokyo, Japan).
To determine the diagnostic capability of whole-body MR imaging with and that without DW imaging for the assessment of M stage in patients with NSCLC, all whole-body DW images and whole-body MR images obtained with and those obtained without DW imaging were prospectively and independently interpreted by two chest radiologists, one with 6 years (H.K.) and the other with 14 years of experience (Y. Ohno), in random order. Both readers were blinded to all information about the results of integrated FDG PET/CT and conventional radiologic examinations. For the assessment of the capability of whole-body DW imaging, precontrast DW images in coronal and sagittal planes (total of two sequences) were interpreted. For the assessment of the capability of whole-body MR imaging without DW imaging, pre-and postcontrast in-phase T1-weighted gradient-echo, precontrast opposedphase T1-weighted gradient-echo, and precontrast STIR turbo spin-echo images in coronal and sagittal planes (total of eight sequences) were interpreted. For the assessment of the capability of whole-body MR imaging with DW imaging, pre-and postcontrast in-phase T1-weighted gradient-echo, precontrast opposed-phase T1-weighted gradientecho, precontrast STIR turbo spinecho, and precontrast DW images in coronal and sagittal planes (total of 10 sequences) were interpreted. The presence or absence of metastases in the head and neck, thorax, abdomen and pelvis, and bone was assessed independently by the same radiologists. The probability of the presence of metastases on a per-patient basis was then evaluated with the following five-point visual scoring system: a score of 1 indicated that metastasis was definitely absent; a score of 2, probably absent; a score of 3, equivocal; a score of 4, probably present; and a score of 5, definitely present. The final determination of M stage on a per-patient basis was made by consensus of the two readers, and sites of metastases were recorded. Reading time of each MR study by each of the readers was recorded. This time was measured from the start of interpretation of images by using the picture archiving and communication system until the recording of whether a metastatic lesion was present or absent at a given site was finished.
To compare the diagnostic capability of whole-body MR imaging with and that without DW imaging with integrated FDG PET/CT for M-stage assessment, all FDG PET/CT studies were prospectively and independently interpreted by two nuclear medicine physicians with 4 and 8 years of experience, respectively (Y. Onishi and M.N.). Both readers were blinded to all information about the results of whole-body MR and conventional radiologic examinations. The presence or absence of metastases in the head and neck, thorax, abdomen and pelvis, and bone was assessed independently by the same readers. The probability of the presence of metastases on a per-patient basis was then evalu-
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Ohno et al ated with the same five-point visual scoring system used for whole-body MR imaging. The final determination of M stage on a per-patient basis was made by consensus of the two readers, and sites of metastases were recorded. Reading time of each FDG PET/CT study by each of the readers was recorded, which was measured from the start of interpretation of images by using the picture archiving and communication system until the recording of whether a metastatic lesion was present or absent at a given site was finished.
Statistical Analysis
A statistic was used to determine the interobserver agreement for wholebody DW imaging, whole-body MR imaging with and that without DW imaging, and integrated FDG PET/CT on a per-patient basis. Because the P values were exploratory in nature, no Bonferroni correction was made. Interobserver agreement was considered to be slight when was less than 0.21, fair when ranged from 0.21 to 0.40, moderate when ranged from 0.41 to 0.60, substantial when ranged from 0.61 to 0.80, and almost perfect when ranged from 0.81 to 1.00 (31) .
To compare the relative convenience of a given modality for diagnosis, the recorded reading times for both readers for each examination were averaged to determine the mean reading time of each examination per subject. The mean reading times for M-stage assessment were then compared among whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and integrated FDG PET/CT by using analysis of variance followed by Tukey honestly significant difference multiple comparison testing.
To determine the feasible threshold value and capability for M-stage assessment with the inclusion of brain metastases, receiver operating characteristic (ROC) analysis was used to compare the diagnostic capability of whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and integrated FDG PET/CT on a per-patient basis. This was followed by a statistical comparison of sensitivity, specificity, and accuracy by means of the McNemar test.
To determine the feasible threshold value and capability for M-stage assessment with the exclusion of brain metastases, ROC analysis was used to compare the diagnostic capability of the four methods on a per-patient basis. This was followed by a statistical comparison of sensitivity, specificity, and accuracy by means of the McNemar test.
A P value less than .05 was considered to indicate a statistically significant difference for all analyses.
Results
All whole-body MR and FDG PET/CT examinations were completed successfully without any adverse effects for any of the radiologic examinations. Representative cases are shown in Figures 1 and 2 .
Details of patient characteristics are shown in Table 1 . Of the 203 patients, 91 had stage I disease, 33 had stage II disease, 39 had stage III disease, and 40 had stage IV disease. Of the patients with stage IV disease, 11 patients had only bone metastases, seven patients had only lung metastases, six patients had only brain metastases, four patients had only lymph node metastases, four patients had only adrenal gland metastases, and four patients had only liver metastases, while two patients had lung, bone, and adrenal gland metastases, one patient had lung and bone metastases, and one patient had liver and abdominal lymph node metastases. Moreover, 93 sites with metastases were detected among the 203 patients with NSCLC, comprising bone metastases (n ϭ 29), lung metastases (n ϭ 26), lymph node metastases (n ϭ 13), brain metastases (n ϭ 9), adrenal gland metastases (n ϭ 8), and liver metastases (n ϭ 8). In addition, 156 cases with other findings were identified, including renal cysts (n ϭ 37), spondylosis (n ϭ 25), benign pulmonary nodules except primary lesions and lung metastases (n ϭ 25), liver cysts (n ϭ 22), hemangiomas in the vertebrae (n ϭ 13) and liver (n ϭ 11), adrenal gland adenomas (n ϭ 7), compression fractures of the vertebrae (n ϭ 6), pancreatic cysts (n ϭ 4), colon polyps (n ϭ 3), normal cervical lymph nodes showing as high-signalintensity areas on DW images (n ϭ 2), and colon cancer (n ϭ 1). Table 2 shows the results on a perpatient basis of the overall scores for assessment of probability of the presence of metastases recorded by the two readers on the basis of whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and FDG PET/CT. The assessments demonstrated that interobserver agreements were substantial.
Results of comparisons of mean reading times for the four methods are shown in Figure 3 . Results of analysis of variance revealed a significant difference among the mean reading times of the four methods (F ϭ 108.1, P Ͻ .001). Mean reading times for M-stage assessment on whole-body DW images (382.4 seconds Ϯ 177.4 [standard deviation]) and whole-body MR images obtained without DW imaging (615.6 seconds Ϯ 284.3) were significantly shorter than those on whole-body MR images obtained with DW imaging (916.8 seconds Ϯ 426.8, P Ͻ .05) and integrated FDG PET/CT images (881.6 seconds Ϯ 419.9, P Ͻ .05).
The results on a per-patient basis of ROC analyses of whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and FDG PET/CT for M-stage assessment inclusive of brain metastases are shown in Table 3 and Figure 4 . The threshold value for the visual scoring system for each method was set at 4. A z values for whole-body MR imaging with DW imaging (P ϭ .04) and integrated FDG PET/CT (P ϭ .02) were significantly larger than that for whole-body DW imaging. Tables 3 and 4 also show the results on a per-patient basis of a comparative analysis of the diagnostic capability, including assessment of brain metastases, of whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and integrated FDG PET/CT; lists of false-positive and false-negative cases for the M-stage assessment in pa-
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Ohno et al tients with NSCLC identified by means of all four methods are included. When brain metastases were included, specificity and accuracy of whole-body MR imaging with (specificity, P ϭ .02; accuracy, P Ͻ .01) and that without DW imaging (specificity, P ϭ .02; accuracy, P ϭ .01) and integrated FDG PET/CT (specificity, P Ͻ .01; accuracy, P Ͻ .01) were significantly higher than those of whole-body DW imaging. With regard to false-positive and false-negative lesions, cases differed from lesion to lesion as well as from patient to patient. The results on a per-patient basis of ROC analyses of whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and FDG PET/CT for M-stage assessment exclusive of brain metastases are shown in Table 5 and Figure 5 . The threshold value for the visual scoring system for each of the methods was set at 4. A z for integrated FDG PET/CT was significantly larger than that for whole-body MR imaging without DW imaging (P ϭ .03).
The results of a comparative analysis on a per-patient basis of the diagnostic capability, with the exclusion of brain metastasis assessment, of wholebody DW imaging, whole-body MR imaging with and that without DW imaging, and integrated FDG PET/CT are also shown in Table 5 . Specificity and accuracy of whole-body MR imaging with DW imaging (specificity, P ϭ .02; accuracy, P ϭ .02) and integrated FDG PET/CT (specificity, P Ͻ .01; accuracy, P Ͻ .01) were significantly higher than those of whole-body DW imaging. Specificity of whole-body MR imaging without DW imaging was significantly higher than that of whole-body DW imaging (P ϭ .02). Accuracy of integrated FDG PET/CT was significantly higher than that of whole-body MR imaging without DW imaging (P Ͻ .01).
Discussion
Our results demonstrate that wholebody MR imaging with DW imaging can be used for M-stage assessment in patients with NSCLC with accuracy as good as that of integrated PET/CT. In addition, when whole-body DW imaging is adopted as an adjunct of wholebody MR examination, the diagnostic capability of whole-body MR examination for M-stage assessment can be enhanced, especially when evaluation of brain metastases at whole-body MR imaging is not included. After tissue diag- 
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Ohno et al nosis of NSCLC has been established, attention should be focused on the determination of the extent of disease, or stage. M-stage assessment is therefore important for determining the appropriate management of this disease, and integrated and/or coregistered FDG PET/CT or PET is currently in wide use. A comparison of interobserver agreement and mean reading time for all four methods showed that interobserver agreements were almost the same and substantial on a per-patient basis. In addition, mean reading time for whole-body MR imaging with DW imaging was not significantly different from that of integrated FDG PET/CT, while mean reading times for wholebody DW imaging and whole-body MR imaging without DW imaging were significantly shorter than those for wholebody MR imaging with DW imaging and integrated PET/CT. Therefore, wholebody MR examination as a conventional screening tool for M-stage assessment in patients with NSCLC may be considered as equivalent to integrated FDG PET/CT in terms of interobserver agreement and time required.
Our results of a comparison of capability for M-stage assessment with the inclusion of brain metastases showed that A z for whole-body DW imaging was significantly smaller than that for wholebody MR imaging with DW imaging and integrated FDG PET/CT. In addition, specificity and accuracy of whole-body DW imaging were significantly lower than those of whole-body MR imaging with and that without DW imaging and integrated FDG PET/CT. These findings suggest that whole-body DW imaging should be considered a less specific and accurate diagnostic tool than integrated FDG PET/CT for M-stage assessment in patients with NSCLC. In addition, although false-positive and false-negative cases differed from lesion to lesion and from patient to patient, lung metastases and pulmonary abnormalities and/or brain metastases accounted for the majority of false-positive and/or false-negative lesions identified with any of the four methods.
Results of previously published studies by many investigators have suggested no MR examinations of any type could have a capability for nodule detection similar to that of CT. In addition, integrated FDG PET/CT data obtained with FDG PET with free-breathing conditions, as well as data obtained with CT alone, have indicated their inferior ca- 
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pability for nodule detection compared with that of routine CT examination with breath holding at end inspiration (32, 33) . Our results are therefore compatible with these previously published results. In addition, with consideration of their capability for detection of brain metastases, detection of small metastases with whole-body DW imaging and integrated FDG PET/CT may be difficult because of the lower contrast ratio between normal cortex and brain metastases than that obtainable with contrastenhanced MR imaging and because of the extremely high level of physiologic tissue accumulation of FDG in the cerebral cortex (20, 34, 35) . Because there seems to be no significant difference in diagnostic accuracy among whole-body MR imaging with and that without DW imaging and integrated FDG PET/CT and in the diagnosis of false-positive and false-negative lesions and cases, wholebody MR imaging with and that without DW imaging can be considered as effective as integrated FDG PET/CT for Mstage assessment with the inclusion of brain metastases.
In view of the aforementioned difficulties at FDG PET or PET/CT for assessment of brain metastases (20, 34, 35) , the guidelines for assessment of TNM staging in NSCLC recommend that contrast-enhanced CT or MR imaging should be used instead of FDG PET or FDG PET/CT for assessment of brain metastases in routine clinical practice. Direct comparison of the diagnostic accuracy for M-stage assessment with the exclusion of brain metastases of all four methods is important for determination of the actual utility of whole-body MR examination. The results of our comparison of the diagnostic capability for Mstage assessment with the exclusion of brain metastases showed that A z for whole-body MR imaging without DW imaging was significantly smaller than that for integrated FDG PET/CT. However, although the diagnostic performance of whole-body DW imaging for M-stage assessment-regardless of whether brain metastases are excluded or not-was lower than that of integrated FDG PET/CT, adoption of whole-body DW imaging as one of the sequences of whole-body MR examination can enhance the diagnostic accuracy of whole-body MR imaging, so that it is no longer significantly different from that of integrated FDG PET/CT. These findings indicate that whole-body DW imaging may be used to direct radiologists' attention to areas of suspected metastases but not for distinguishing malignant from benign lesions by using visual assessment of signal intensity, as was previously reported for apparent diffusion coefficient (36, 37) . In addition, whole-body MR imaging with DW imaging can be considered as effective for M-stage assessment as in- (38) , while angiogenesis occurs in most tumors with a diameter of 1-2 mm (39, 40) . These findings suggest that we may have missed some suspect metastatic sites that could not be detected with any of the four methods. Second, although we ensured that the final M-stage and metastasis of a given site were decided by consensusbased on the results of standard imaging; pathologic results from endoscopic, CT-guided, or surgical biopsies; and results of follow-up examinations performed for more than 12 months-at a conference attended by radiologists, radiation oncologists, pathologists, oncologists, and surgeons with more than 10 years of experience, the final M stage and metastasis of a given site could not be diagnosed in every patient at pathologic examination; some sensitivity and specificity results of our study may have been biased because of incomplete
Figures 4, 5
Figure 4: Graph of ROC analyses of whole-body DW imaging (E), whole-body MR imaging with (f) and that without DW imaging (Ⅺ), and integrated FDG PET/CT (F) for M-stage assessment inclusive of brain metastases on a per-patient basis in patients with NSCLC shows A z for whole-body MR imaging with DW imaging (P ϭ .04) and integrated FDG PET/CT (P ϭ .02) as significantly larger than that for whole-body DW imaging. Figure 5 : Graph of ROC analyses of whole-body DW imaging (E), whole-body MR imaging with (f) and that without DW imaging (Ⅺ), and integrated FDG PET/CT (F) for M-stage assessment exclusive of brain metastases on a per-patient basis in patients with NSCLC shows A z for integrated FDG PET/CT as significantly larger than that for whole-body MR imaging without DW imaging (P ϭ .03). THORACIC IMAGING: M-Stage Assessment in Non-Small Cell Lung Cancer Ohno et al pathologic sampling. However, these limitations might bias estimates of the absolute accuracy of whole-body MR and integrated FDG PET/CT examinations, and one might expect these biases to affect both modalities relatively equally. Therefore, the difference between the modalities may be less affected by such bias.
Third, to implement whole-body MR imaging in routine clinical practice, development of a workstation and performance of further investigations for the determination of feasible sequences for whole-body MR imaging on a persite basis may be warranted. In addition, standardization of sequences for M-stage assessment by using wholebody MR imaging with DW imaging and improvement of MR systems for wholebody examination are necessary to adopt this method for routine clinical practice and to substitute it for integrated FDG PET/CT.
Fourth, although interobserver agreement, mean reading time, and diagnostic capability for initial M-stage as- Table 4 False (41) (42) (43) suggest that integrated PET/CT should be considered as having diagnostic accuracy equal to or higher than that of conventional radiologic imaging or PET alone in other malignancies. In addition, these study results also suggest the limitation of integrated PET/CT and the way for using it together with conventional radiologic imaging in these malignancies. Therefore, direct comparison among the above-mentioned four methods and standard radiologic examinations may also be warranted to determine the real clinical importance of whole-body MR imaging with DW imaging and integrated FDG PET/CT for M-stage assessment in patients with NSCLC. We will plan a study in the near future to prospectively and directly compare clinical utility for M-stage assessment in patients with NSCLC among whole-body MR imaging, integrated FDG PET/CT, standard radiologic examinations, and combinations of techniques discussed in this article in a large prospective cohort.
In conclusion, whole-body MR imaging with DW imaging can be used for M-stage assessment in patients with NSCLC with accuracy as good as that of integrated PET/CT; in addition, when whole-body DW imaging is adopted as an adjunct for whole-body MR imaging without whole-body DW imaging, the diagnostic accuracy of whole-body MR examination can be improved.
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